Arnold Ganser
Overview
Explore the profile of Arnold Ganser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
475
Citations
18514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hupe H, Wienecke C, Bartels S, Schipper E, Lessmann J, Lasch A, et al.
Hemasphere
. 2025 Mar;
9(3):e70097.
PMID: 40066001
Isolated extramedullary manifestations (IEM) of acute myeloid leukemia (AML) are recurrent events, especially following allogeneic hematopoietic cell transplantation (alloHCT). To date, measurable residual disease (MRD) assessment for this difficult-to-treat patient...
2.
Cocciardi S, Saadati M, Weiss N, Spath D, Kapp-Schwoerer S, Schneider I, et al.
Hemasphere
. 2025 Jan;
9(1):e70060.
PMID: 39816531
This study aimed to evaluate the impact of the myelodysplasia-related gene (MRG) as well as additional gene mutations on outcomes in intensively treated patients with -mutated ( ) AML. Targeted...
3.
4.
Silva W, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P, et al.
Haematologica
. 2024 Oct;
110(3):795-798.
PMID: 39479861
No abstract available.
5.
Larue M, Labopin M, Schroeder T, Huang X, Blau I, Schetelig J, et al.
Hemasphere
. 2024 Oct;
8(10):e70026.
PMID: 39440198
Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left-truncated analysis of long-term survival in patients with...
6.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, et al.
Eur J Haematol
. 2024 Oct;
114(2):231-237.
PMID: 39400388
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also...
7.
Rucker F, Bullinger L, Cocciardi S, Skambraks S, Luck T, Weber D, et al.
Blood Adv
. 2024 Sep;
8(23):6067-6080.
PMID: 39348668
Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently...
8.
Shahswar R, Ganser A
Expert Rev Hematol
. 2024 Sep;
17(10):723-739.
PMID: 39246164
Introduction: The combined use of the BCL-2 inhibitor venetoclax with azacitidine now is the standard of care for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy with outcomes...
9.
Mohty R, Bazarbachi A, Labopin M, Esteve J, Kroger N, Cornelissen J, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1534-1541.
PMID: 39143183
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations have uncertain prognostic implications in AML. We investigate the impact IDH1 and IDH2 mutations in AML patients undergoing allogeneic hematopoietic cell...
10.
Rucker F, Corbacioglu A, Krzykalla J, Cocciardi S, Lengerke C, Germing U, et al.
Hemasphere
. 2024 Jul;
8(7):e123.
PMID: 39011127
No abstract available.